VolitionRX appoints high profile cancer consultant to boost funding in Texas

Over the past six years Vollmer Dahlke has raised over US$25mln in non-dilutive grants

picture of Texas flag
Volition America has set up in Texas

VolitionRx Limited’s (NYSE:VNRX) US subsidiary Volition America has appointed Dr Deborah Vollmer Dahlke as a strategic consultant to help it get funding in Texas and elsewhere in the US.

Over the past six years Vollmer Dahlke has raised over US$25mln in non-dilutive grants from the Cancer Prevention and Research Institute of Texas (CPRIT) for her clients.

She is a director of the Texas Life Science Foundation and is actively involved in helping to develop Texas's biotech funding infrastructure as well as being one of several authors of the current Texas Cancer Plan, one of CPRIT's legislative requirements.

This aims to co-ordinate, prioritize and provide an actionable framework to fight the effects of cancer in Texas.

Jason Terrell Volition America’s chief executive, said: "We are delighted to be working with Dr. Vollmer Dahlke to help identify and secure funding to further our development of blood-based cancer diagnostic tests for the US.

“The fact that Texas is one of the leading life science states was a key driver in our decision to make this the home of Volition America, Inc.” 

Shares nudged 1.19% higher in New York  to stand at $4.25.

Quick facts: VolitionRx

Price: 3.28 USD

Market Cap: $151.62 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...



Proactive One2One Virtual Event - VolitionRX

VolitionRx Limited's (NYSE AMERICAN:VNRX) Scott Powell presents to investors at Proactive's One2One Virtual Event. Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. 

12 hours, 31 minutes ago

2 min read